Europe Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As Europe rethinks the balance between affordability, resilience and innovation, Michal Nitka, SVP, Head Generics Europe & Global Head OTC at…
Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…
USA Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its…
Europe As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over the past five years through increased investment in R&D, manufacturing, and international expansion, the company is building on the scientific…
Greece The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare resilience, expand internationally and support Greece’s emergence as a strategic pharmaceutical manufacturing hub, while reflecting on the policy choices that…
USA Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s growth into a top-five US injectable generic player, its expansion into biosimilars, and its commitment to manufacturing investment, supply reliability,…
USA We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the healthcare system’s efforts to improve affordability, strengthen supply resilience, and expand patient access to medicines. As Cipla enters its second…
USA A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for Accessible Medicines. Following leadership changes within the FDA, actively prioritizing generic and biosimilar medicines must remain a top focus…
Taiwan Taiwan runs one of the most cost-effective universal healthcare systems in the world, delivering near-universal coverage to 23 million people at a fraction of what comparable systems cost elsewhere. At the foundation of that achievement sits a network of domestic generic and OTC manufacturers, several of them family-owned businesses now…
Taiwan Petar Vazharov, CEO of Lotus Pharmaceuticals, is a medical doctor with an MBA who joined Alvogen in 2009 as one of its first international hires. After building the company’s Central and Eastern European business, he spent the past decade transforming Lotus – driving seven consecutive years of double-digit growth, expanding…
Europe Few European pharmaceutical companies have undergone a transformation as striking as STADA’s. From its roots as a German generics business, the group has evolved into a diversified healthcare player with growing strength across Generics, Consumer Healthcare, and Specialty Pharmaceuticals, underpinned by an entrepreneurial culture and an increasingly important presence across…
Europe Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term resilience, affordability, and supply security. CEO Steffen Saltofte reflects on the company’s transformation since its carve out from Sanofi, its…
See our Cookie Privacy Policy Here
